News
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making ... patient population for the drug significantly. AZ estimates that approximately 70% of breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback